Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
HNGE has a shareholder planning to sell 131,057 Class A shares through Merrill Lynch on the NYSE, with an aggregate market value of $6,409,997.87. The filing notes that 37,919,155 shares of this class are outstanding. The shares to be sold were originally acquired from the issuer in a private placement on 07/03/2018 for cash.
HNGE has a shareholder filing a Form 144 notice to sell up to 677,508 Class A shares through Merrill Lynch on the NYSE, with an approximate aggregate market value of $33,136,916.28. The filing notes that there were 37,919,155 shares of this class outstanding when the notice was prepared and that the proposed sales may begin on 12/01/2025. The shares were originally acquired from the issuer in a private placement on 07/03/2018 and paid for in cash.
HNGE reported that a holder of its Class A stock has filed a notice of proposed sale under Rule 144. The holder plans to sell 826,216 Class A shares through Merrill Lynch on the NYSE, with an approximate sale date of 12/01/2025. The filing lists an aggregate market value for these shares of $40,410,224.56. These Class A shares were originally acquired from the issuer in a private placement on 07/03/2018 and paid for in cash. The notice also states that 37,919,155 shares of this class were outstanding, providing a baseline for the size of the proposed sale.
Hinge Health, Inc. reported an insider equity transaction by its President on 12/01/2025. The filing shows that 5,126 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $48.91 per share. This type of code indicates shares were withheld or surrendered to cover taxes associated with the vesting of restricted stock units, rather than being sold on the open market.
After this tax-related share cancellation, the reporting officer beneficially owns 784,776 shares of Class A common stock directly. The issuer satisfied the related federal and state tax withholding obligations in exchange for the relinquished shares, leaving the executive with a substantial continuing equity stake in the company.
Hinge Health, Inc.'s Chief Financial Officer reported a routine share disposition related to tax withholding on equity compensation. On 12/01/2025, the reporting person disposed of 8,213 shares of Class A common stock at $48.91 per share in an exempt transaction. After this transaction, the officer beneficially owned 471,665 shares directly.
The company explains that the shares were withheld and cancelled by the issuer to cover federal and state tax obligations arising from the vesting of restricted stock units, as permitted under Section 16b-3(e). This reflects standard administrative handling of equity awards rather than an open-market sale.
HNGE shareholder(s) filed a Form 144 notice to sell Class A common stock. The filing covers a proposed sale of 21,757 Class A shares through Merrill Lynch, with an aggregate market value of 1,088,937.85. The shares relate to a private placement acquisition on 02/04/2020, paid for in cash.
The filing notes that 37,919,155 Class A shares were outstanding at the time of the notice. It also discloses recent sales by affiliated Bessemer Venture Partners funds in November 2025, including blocks of 373,955, 103,160, 351,045 and 96,840 Class A shares, with individual transaction gross proceeds between 4,674,466.8 and 14,976,898. The seller represents they are not aware of undisclosed material adverse information about HNGE.
HNGE has a Form 144 notice indicating that a stockholder plans to sell 23,176 shares of Class A common stock through Merrill Lynch on the NYSE, with an approximate sale date of 11/28/2025. The aggregate market value of the shares to be sold is listed as 1,159,958.8, and the total number of Class A shares outstanding is shown as 37,919,155.
The shares to be sold were acquired on 02/04/2020 in a private placement from the issuer for cash. Over the past three months, Bessemer Venture Partners X LP and Bessemer Venture Partners X Institutional LP together sold several Class A share blocks, including 373,955 and 103,160 shares for gross proceeds of 14,976,898 and 4,979,533.2, and 351,045 and 96,840 shares for gross proceeds of 14,059,352 and 4,674,466.8.
Hinge Health, Inc. (HNGE) Chief Financial Officer James Budge reported open-market sales of Class A common stock under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. On November 25, 2025, he sold 15,730 shares at a weighted average price of $46.8822, 27,248 shares at a weighted average price of $47.7669, and 1,611 shares at a weighted average price of $48.2738, across specified price ranges. Following these transactions, Budge beneficially owned 479,878 shares of Hinge Health Class A common stock in direct ownership.
Hinge Health, Inc. (HNGE) President insider sale reported. A company officer filed a Form 4 showing open-market sales of a total of 15,000 shares of Class A common stock on 11/21/2025, executed in three transactions.
The shares were sold at weighted average prices of $44.3538, $45.7528, and $46.0885, within disclosed price ranges from $43.96 to $46.21. The transactions were made under a Rule 10b5-1 trading plan adopted on June 12, 2025. Following these sales, the reporting person directly holds 789,902 shares of Class A common stock.
Hinge Health, Inc. (HNGE) reported an insider stock sale by one of its directors. On 11/21/2025, the reporting person sold 1,250 shares of Class A common stock in an open-market transaction coded as "S" at a weighted average price of $45.6848 per share, within a range of $45.68 to $45.71.
After this transaction, the director beneficially owns 27,750 shares of Hinge Health Class A common stock directly. No derivative securities transactions were reported in this filing.